Back to Search Start Over

HFE and ALK3 act in the same signaling pathway.

Authors :
Traeger L
Schnittker J
Dogan DY
Oguama D
Kuhlmann T
Muckenthaler MU
Krijt J
Urzica EI
Steinbicker AU
Source :
Free radical biology & medicine [Free Radic Biol Med] 2020 Nov 20; Vol. 160, pp. 501-505. Date of Electronic Publication: 2020 Aug 27.
Publication Year :
2020

Abstract

Hepcidin deficiency leads to iron overload by increased dietary iron uptake and iron release from storage cells. The most frequent mutation in Hfe leads to reduced hepcidin expression and thereby causes iron overload. Recent findings suggested that HFE activates hepcidin expression predominantly via the BMP type I receptor ALK3. Here, we investigated whether HFE exclusively utilizes ALK3 or other signaling mechanisms also. We generated mice with double deficiency of Hfe and hepatocyte-specific Alk3 and compared the iron overload phenotypes of these double knockout mice to single hepatocyte-specific Alk3 deficient or Hfe knockout mice. Double Hfe <superscript>-/-</superscript> /hepatic Alk3 <superscript>fl/fl</superscript> ;Alb-Cre knockouts develop a similar iron overload phenotype compared to single hepatocyte-specific Alk3 deficient mice hallmarked by serum iron levels, tissue iron content and hepcidin levels of similar grades. HFE protein levels were increased in Alk3 <superscript>fl/fl</superscript> ;Alb-Cre mice compared to Alk3 <superscript>fl/fl</superscript> mice, which was caused by iron overload - and not by Alk3 deficiency. The data provide evidence by genetic means that 1. HFE exclusively uses the BMP type I receptor ALK3 to induce hepcidin expression and 2. HFE protein expression is induced by iron overload, which further emphasizes the iron sensing function of HFE.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1873-4596
Volume :
160
Database :
MEDLINE
Journal :
Free radical biology & medicine
Publication Type :
Academic Journal
Accession number :
32861780
Full Text :
https://doi.org/10.1016/j.freeradbiomed.2020.08.023